Leading the way to safer medication
 Crosscheck  Recommender

Basiliximab

Description

Basiliximab is a murine/human chimeric monoclonal antibody (IgG1κ) that is directed against the interleukin-2 receptor α-chain (CD25 antigen), which is expressed on the surface of T-lymphocytes in response to antigenic challenge. Basiliximab specifically binds with high affinity (KD-value 0.1 nM) to the CD25 antigen on activated T-lymphocytes expressing the high affinity interleukin-2 receptor (IL-2R) and thereby prevents binding of interleukin-2, a critical signal for T-cell proliferation in the cellular immune response involved in allograft rejection.

Medicine classification

ATC Code
Title
Class
L04AC02
Basiliximab
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors

Medicines

Drug
Countries

Austria Canada Cyprus France Lithuania

Product monographs

Monograph
Type
Country
SIMULECT Powder and solvent for solution for injection
MPI, EU: SmPC